JP2024506387A - 腎線維症を治療するためのオキサジアゾリルジヒドロピラノ［２，３‐ｂ］ピリジン系ＨＩＰＫ２阻害剤 - Google Patents

腎線維症を治療するためのオキサジアゾリルジヒドロピラノ［２，３‐ｂ］ピリジン系ＨＩＰＫ２阻害剤 Download PDF

Info

Publication number
JP2024506387A
JP2024506387A JP2023548877A JP2023548877A JP2024506387A JP 2024506387 A JP2024506387 A JP 2024506387A JP 2023548877 A JP2023548877 A JP 2023548877A JP 2023548877 A JP2023548877 A JP 2023548877A JP 2024506387 A JP2024506387 A JP 2024506387A
Authority
JP
Japan
Prior art keywords
water
hco
mmol
conditions
under
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023548877A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024506387A5 (https=
Inventor
ティ． ベレシス，リチャード
ツゥジアン ヘ，ジョン
イ，ギョン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Icahn School of Medicine at Mount Sinai
Original Assignee
Icahn School of Medicine at Mount Sinai
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Icahn School of Medicine at Mount Sinai filed Critical Icahn School of Medicine at Mount Sinai
Publication of JP2024506387A publication Critical patent/JP2024506387A/ja
Publication of JP2024506387A5 publication Critical patent/JP2024506387A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
JP2023548877A 2021-02-10 2022-02-09 腎線維症を治療するためのオキサジアゾリルジヒドロピラノ［２，３‐ｂ］ピリジン系ＨＩＰＫ２阻害剤 Pending JP2024506387A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163147859P 2021-02-10 2021-02-10
US63/147,859 2021-02-10
PCT/US2022/015767 WO2022173795A1 (en) 2021-02-10 2022-02-09 OXADIAZOLYL DIHYDROPYRANO[2,3-b]PYRIDINE INHIBITORS OF HIPK2 FOR TREATING KIDNEY FIBROSIS

Publications (2)

Publication Number Publication Date
JP2024506387A true JP2024506387A (ja) 2024-02-13
JP2024506387A5 JP2024506387A5 (https=) 2025-01-27

Family

ID=82837244

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023548877A Pending JP2024506387A (ja) 2021-02-10 2022-02-09 腎線維症を治療するためのオキサジアゾリルジヒドロピラノ［２，３‐ｂ］ピリジン系ＨＩＰＫ２阻害剤

Country Status (9)

Country Link
US (1) US20250179084A1 (https=)
EP (1) EP4291183B1 (https=)
JP (1) JP2024506387A (https=)
KR (1) KR20230154194A (https=)
CN (1) CN117479934A (https=)
AU (1) AU2022221336A1 (https=)
CA (1) CA3210658A1 (https=)
MX (1) MX2023009323A (https=)
WO (1) WO2022173795A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240051965A1 (en) * 2022-08-05 2024-02-15 Icahn School Of Medicine At Mount Sinai Oxygen-containing heterocyclic compound and use thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100168005A1 (en) * 2006-09-08 2010-07-01 Actelion Pharmaceuticals Ltd. Pyridin-3-yl derivatives as immunomodulating agents
US20100174065A1 (en) * 2007-12-21 2010-07-08 Glaxo Group Limited Compounds
US20110274657A1 (en) * 2009-01-19 2011-11-10 Nuria Aguilar Izquierdo Oxadiazole derivatives as s1p1 receptor antagonists
WO2018129274A1 (en) * 2017-01-06 2018-07-12 Icahn School Of Medicine At Mount Sinai Oxadiazole inhibitors of hipk2 for treating kidney fibrosis
WO2018231745A1 (en) * 2017-06-14 2018-12-20 Trevena, Inc. Compounds for modulating s1p1 activity and methods of using the same

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100168005A1 (en) * 2006-09-08 2010-07-01 Actelion Pharmaceuticals Ltd. Pyridin-3-yl derivatives as immunomodulating agents
US20100174065A1 (en) * 2007-12-21 2010-07-08 Glaxo Group Limited Compounds
US20110274657A1 (en) * 2009-01-19 2011-11-10 Nuria Aguilar Izquierdo Oxadiazole derivatives as s1p1 receptor antagonists
WO2018129274A1 (en) * 2017-01-06 2018-07-12 Icahn School Of Medicine At Mount Sinai Oxadiazole inhibitors of hipk2 for treating kidney fibrosis
WO2018231745A1 (en) * 2017-06-14 2018-12-20 Trevena, Inc. Compounds for modulating s1p1 activity and methods of using the same

Also Published As

Publication number Publication date
MX2023009323A (es) 2023-12-14
WO2022173795A1 (en) 2022-08-18
US20250179084A1 (en) 2025-06-05
CN117479934A (zh) 2024-01-30
EP4291183A1 (en) 2023-12-20
AU2022221336A1 (en) 2023-08-24
EP4291183B1 (en) 2026-04-08
KR20230154194A (ko) 2023-11-07
EP4291183A4 (en) 2025-01-08
CA3210658A1 (en) 2022-08-18

Similar Documents

Publication Publication Date Title
JP6982054B2 (ja) Ｇｌｐ−１受容体アゴニストおよびその使用
JP7553450B2 (ja) ユビキチン特異的プロテアーゼ１を阻害するための組成物
EP4219487B9 (en) Glp-1 receptor agonists and uses thereof
CA2237221C (en) Protein kinase c inhibitor
JP5820921B2 (ja) １，２−二置換複素環式化合物
KR20250047778A (ko) 삼환식 화합물 및 그의 의약 용도
TW202112761A (zh) Shp2磷酸酶變構抑制劑
JP7187575B2 (ja) Ｒｈｏキナーゼ阻害剤としてのベンゾピラゾール系化合物
CN116332938A (zh) 稠合三环类衍生物及其制备方法和用途
KR20150112953A (ko) 테트라하이드로- 및 디하이드로-이소퀴놀린 prmt5 억제제 및 이의 용도
JP7618338B2 (ja) ３－アザビシクロアルキル誘導体およびこれを含む薬剤学的組成物
JP2023539275A (ja) 新規なｒｈｏ関連タンパク質キナーゼ阻害剤の調製方法およびその調製方法における中間体
CN116120296A (zh) 一种多环化合物、包含其的药物组合物、其制备方法及其用途
EA033827B1 (ru) Производные бензимидазола в качестве антигистаминных агентов
JP2024506387A (ja) 腎線維症を治療するためのオキサジアゾリルジヒドロピラノ［２，３‐ｂ］ピリジン系ＨＩＰＫ２阻害剤
KR20240154590A (ko) Lpa 수용체 활성과 연관된 상태를 치료하기 위한 화합물 및 조성물
CN113045569B (zh) 用作ret激酶抑制剂的化合物及其应用
ES2347593T3 (es) Nuevos derivados ciclicos sustituidos de furopirimidina y su uso para el tratamiento de enfermedades cardiobasculares.
KR20220090553A (ko) Ssao 억제제 및 그의 용도
JP2025534417A (ja) 免疫抑制化合物
CN111848572A (zh) 酰胺类化合物及其制备方法和用途
WO2023116763A1 (zh) 一种哒嗪类化合物、其药物组合物及应用
CN103906751A (zh) 作为晚期SV40因子（LSF）抑制剂用于治疗癌症的[1,3]二氧杂环戊烯并[4,5-g]喹啉-6(5H)-硫酮和[1,3]二氧杂环戊烯并[4,5-g][1,2,4]三唑并[1,5-a]喹啉衍生物
TW202430505A (zh) 萘醯胺類化合物、其製備方法及其應用
RU2819762C1 (ru) Соединение в качестве ингибитора циклинзависимой киназы 9 и его применение

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250117

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250117

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251014

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260106

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260324